Zusammenfassung
In den bundesweiten Surveys des Robert Koch-Instituts zur Gesundheit von Kindern, Jugendlichen (KiGGS) und Erwachsenen (DEGS1) wird die aktuelle Arzneimittelanwendung in den letzten 7 Tagen vor der Untersuchung durch ein standardisiertes ärztliches Interview erfasst. Etwa die Hälfte der Kinder und Jugendlichen (50,8%) und drei Viertel aller Erwachsenen (74,7%) geben an, in diesem Zeitraum mindestens ein Präparat angewendet zu haben. Die höchsten Anwendungsprävalenzen weisen Kinder im Alter von 0 bis 2 Jahren (74,9%) sowie 70- bis 79-jährige Frauen und Männer (96,3% vs. 94,9%) auf. Im Erwachsenenalter dominieren Arzneimittel zur Behandlung chronisch-degenerativer Erkrankungen, im Kindes- und Jugendalter sind es Präparate, die bei akuten Erkrankungen, Gesundheitsstörungen und zur Prävention eingesetzt werden. Die dargestellten Ergebnisse beschreiben wesentliche Eckpunkte des Arzneimittelgebrauchs repräsentativ für die Wohnbevölkerung in Deutschland.
Abstract
The Robert Koch Institute’s national health interview and examination surveys for children and adolescents (KiGGS) and for adults (DEGS1) assess the use of medication in the 7 days prior to the medical examination as part of a standardized interview. About half of the children and adolescents (50.8%) and nearly three quarters of all adults (74.7%) state that they used at least one drug. The highest prevalences were detected among 0- to 2-year olds (74.9%) and 70- to 79-year-old women and men (96.3% vs. 94.9%). The medications used most frequently were drugs for the treatment of chronic degenerative diseases (in adulthood), drugs for the therapy of acute diseases and symptoms as well as for preventive indications (in childhood and adolescence). The results presented here describe key indicators of medication use representative of the resident population in Germany.
Autorenerklärung
Autorenbeteiligung: Alle Autoren tragen Verantwortung für den gesamten Inhalt dieses Artikels und haben der Einreichung des Manuskripts zugestimmt. Finanzierung: Die Autoren erklären, dass sie keine finanzielle Förderung erhalten haben. Interessenkonflikt: Die Autoren erklären, dass kein wirtschaftlicher oder persönlicher Interessenkonflikt vorliegt. Ethische Statement: In Übereinstimmung mit der Deklaration von Helsinki wurden die Teilnehmer über das genaue Verfahren der Studie informiert und haben freiwillig teilgenommen. Alle Teilnehmer gaben ihre Zustimmung. Die Studie wurde von der Ethikkommission der Charite Berlin zugelassen.
Author Declaration
Author contributions: All authors have accepted responsibility for the entire content of this submitted manuscript and approved submission. Funding: Robert Koch Institut. Conflict of interest: Authors state no conflict of interest. Ethical statement: In accordance with the Helsinki Declaration, the participants were informed about the exact procedure of the study and took part voluntarily. All participants gave their approval. The study was approved by the Ethics Commission of the Charite Berlin.
Literatur
1. Schaufler J, Telschow C. Arzneiverordnungen nach Alter und Geschlecht. In: Schwabe U, Paffrath D, editors. Arzneiverordnungs-Report 2013. Aktuelle Daten, Kosten, Trends und Kommentare. Berlin: Springer, 2014:1077–95.Search in Google Scholar
2. Schwabe U. Arzneimittelverordnungen im Kindesalter. In: Schwabe U, Paffrath D, editors. Arzneiverordnungs-Report 2005. Aktuelle Daten, Kosten, Trends und Kommentare. Heidelberg: Springer, 2005:993–1049.Search in Google Scholar
3. Glaeske G, Schicktanz C. BARMER GEK Arzneimittelreport 2013. Auswertungsergebnisse der BARMER GEK Arzneimitteldaten aus den Jahren 2011 bis 2012. Siegburg: Asgard Verlagsservice GmbH, 2013.Search in Google Scholar
4. Knopf H. [Medicine use in children and adolescents. Data collection and first results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2007;50:863–70.10.1007/s00103-007-0249-zSearch in Google Scholar PubMed
5. Knopf H, Grams D. [Medication use of adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2013;56:868–77.10.1007/s00103-013-1667-8Search in Google Scholar PubMed
6. Bellach B-M, Knopf H, Thefeld W. Der Bundes-Gesundheitssurvey 1997/98. Gesundheitswesen 1998;60:59–68.Search in Google Scholar
7. Kurth BM. [The German Health Interview and Examination Survey for Children and Adolescents (KiGGS): an overview of its planning, implementation and results taking into account aspects of quality management]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2007;50:533–46.10.1007/s00103-007-0214-xSearch in Google Scholar PubMed
8. Scheidt-Nave C, Kamtsiuris P, Gosswald A, Hölling H, Lange M, Busch MA, et al. German health interview and examination survey for adults (DEGS) – design, objectives and implementation of the first data collection wave. BMC public health 2012;12:730.10.1186/1471-2458-12-730Search in Google Scholar PubMed PubMed Central
9. Knopf H, Hölling H, Huss M, Schlack R. Prevalence, determinants and spectrum of attention-deficit hyperactivity disorder (ADHD) medication of children and adolescents in Germany: results of the German Health Interview and Examination Survey (KiGGS). BMJ Open 2012;2:e000477. doi:10.1136/bmjopen-2011-000477.10.1136/bmjopen-2011-000477Search in Google Scholar PubMed PubMed Central
10. Schubert I, Koster I, Lehmkuhl G. The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000–2007. Dtsch Arztebl Int 2010;107:615–21.Search in Google Scholar
11. Acquaviva E, Legleye S, Auleley GR, Deligne J, Carel D, Falissard BB. Psychotropic medication in the French child and adolescent population: prevalence estimation from health insurance data and national self-report survey data. BMC Psychiatry 2009;9:72.10.1186/1471-244X-9-72Search in Google Scholar PubMed PubMed Central
12. Zito JM, Safer DJ, Janhsen K, Fegert JM, Gardner JF, Glaeske G, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health 2008;2:26.10.1186/1753-2000-2-26Search in Google Scholar PubMed PubMed Central
13. Zuvekas SH, Vitiello B, Norquist GS. Recent trends in stimulant medication use among U.S. children. Am J Psychiatry 2006;163:579–85.10.1176/ajp.2006.163.4.579Search in Google Scholar
14. Sawyer MG, Rey JM, Graetz BW, Clark JJ, Baghurst PA. Use of medication by young people with attention-deficit/hyperactivity disorder. Med J Aust 2002;177:21–5.10.5694/j.1326-5377.2002.tb04624.xSearch in Google Scholar PubMed
15. Knopf H, Wolf IK, Sarganas G, Zhuang W, Rascher W, Neubert A. Off-label medicine use in children and adolescents: results of a population-based study in Germany. BMC Public Health 2013;13:631.10.1186/1471-2458-13-631Search in Google Scholar PubMed PubMed Central
16. Du Y, Knopf H. Self-medication among children and adolescents in Germany: results of the National Health Survey for Children and Adolescents (KiGGS). Br J Clin Pharmacol 2009;68: 599–608.10.1111/j.1365-2125.2009.03477.xSearch in Google Scholar PubMed PubMed Central
17. Eckel N, Sarganas G, Wolf IK, Knopf H. Pharmacoepidemiology of common colds and upper respiratory tract infections in children and adolescents in Germany. BMC Pharmacol Toxicol 2014;15:44.10.1186/2050-6511-15-44Search in Google Scholar PubMed PubMed Central
18. Du Y, Knopf H. Paediatric homoeopathy in Germany: results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Pharmacoepidemiol Drug Saf 2009;18:370–9.10.1002/pds.1720Search in Google Scholar PubMed
19. Du Y, Wolf IK, Zhuang W, Bodemann S, Knoss W, Knopf H. Use of herbal medicinal products among children and adolescents in Germany. BMC Complement Altern Med 2014;14:218.10.1186/1472-6882-14-218Search in Google Scholar PubMed PubMed Central
20. Du Y, Ellert U, Zhuang W, Knopf H. Analgesic use in a national community sample of German children and adolescents. Eur J Pain 2012;16:934–43.10.1002/j.1532-2149.2011.00093.xSearch in Google Scholar PubMed
21. Koch-Institut R. Bundes-Gesundheitssurvey: Arzneimittelgebrauch. Konsumverhalten in Deutschland. Berlin, 2003.Search in Google Scholar
22. Lai SW, Liao KF, Liao CC, Muo CH, Liu CS, Sung FC. Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. Medicine 2010;89:295–9.10.1097/MD.0b013e3181f15efcSearch in Google Scholar PubMed
23. Haider SI, Johnell K, Thorslund M, Fastbom J. Trends in polypharmacy and potential drug-drug interactions across educational groups in elderly patients in Sweden for the period 1992–2002. International journal of clinical pharmacology and therapeutics 2007;45:643–53.10.5414/CPP45643Search in Google Scholar
24. Ziere G, Dieleman JP, Hofman A, Pols HA, Van Der Cammen TJ, Stricker BH. Polypharmacy and falls in the middle age and elderly population. Br J Clin Pharmacol 2006;61:218–23.10.1111/j.1365-2125.2005.02543.xSearch in Google Scholar PubMed PubMed Central
25. Knopf H. [Self-medication with vitamins, minerals and food supplements in Germany: Results of nationwide health surveys]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2017;60:268–76.10.1007/s00103-016-2500-ySearch in Google Scholar PubMed
26. Sarganas G, Buttery AK, Zhuang W, Wolf IK, Grams D, Rosario AS, et al. Prevalence, trends, patterns and associations of analgesic use in Germany. BMC Pharmacol Toxicol 2015;16:28.10.1186/s40360-015-0028-7Search in Google Scholar PubMed PubMed Central
27. Kroth E. Switch – Wie steht Deutschland im internationalen Vergleich da? Gesundh ökon Qual manag 2017;22:3–11.10.1055/s-0042-120484Search in Google Scholar
©2017 Walter de Gruyter GmbH, Berlin/Boston
